DelveInsight’s “Hand Eczema Market” report delivers an in-depth understanding of Hand Eczema, historical and forecasted epidemiology, and the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.

Key takeaways from the Hand Eczema Market Report:

• As per DelveInsight analysis, the Hand Eczema market was found to be approx USD 11.5 billion in the 7MM in 2021. 

• As per our estimates, the prevalence of the Hand Eczema market was 63 million approx cases in the 7MM in 2021.

• Leading companies in the Hand Eczema market include Basilea Pharmaceutica, Stiefel Laboratories, Regeneron, Sanofi, Leo Pharma, Japan Tobacco Inc., Incyte Corporation, Asana Biosciences, and others are developing novel Hand Eczema drugs which can be available in the market in the upcoming years.

• Promising emerging Hand Eczema therapies in the pipeline include Delgocitinib, Ruxolitinib, ASN002, and others.

• The current understanding of Hand Eczema has greatly improved in recent decades. It has led to advancements, greater results, and newer therapies. 

Hand Eczema Overview 

Hand Eczema, also known as hand dermatitis, stands among the most common type of eczema. The symptoms of Hand Eczema majorly can be seen on the palms and other parts of the hand. The key symptoms that indicate Hand Eczema include dryness, itching, scaly skin, and inflammation affecting the palm or whole hand, including the fingers. Other symptoms may include cracking, soreness and bleeding.

In order to diagnose the disease, the major approaches a  physician can opt for are studying patients’ history, signs, and symptoms and evaluating atopy. 

Learn more about the Hand Eczema epidemiology @ Hand Eczema  Epidemiology Analysis

Hand Eczema Epidemiology

As per Delveinsight, the prevalence of Hand Eczema was approx. 63 million cases in the 7MM in 2021. Among the EU5, Germany had the highest prevalent cases in 2021.

Hand Eczema Epidemiology Segmentation

• Total Prevalent Cases

• Gender-specific Cases

• Type Specific Cases  

• Severity-Specific Cases

• Subgroup-Specific Cases

Hand Eczema Treatment Market

The treatment and management of Hand Eczema is still not defined. However, it majorly includes skin hydration, use of emollients, avoidance of irritants, and therapeutic intervention with topical corticosteroids (TCS). It also includes the usage of systemic immunosuppressive therapies such as short-term oral corticosteroids, azathioprine, methotrexate, retinoids, and cyclosporine. 

The present market landscape of Hand Eczema therapies is classified into four groups: topical corticosteroids, topical calcineurin inhibitors, UV therapy including PUVA, and others (Iontophoresis therapy, other topical therapies, salicylic acid, etc.). 

Get more information about the current treatment pattern and emerging pipeline therapies @ Hand Eczema Treatment Drugs

Hand Eczema Pipeline Therapies and Key Companies 

• Delgocitinib: Leo Pharma/ Japan Tobacco Inc.

• Ruxolitinib: Incyte Corporation

• ASN002: Asana Biosciences 

Hand Eczema Market Dynamics

New advancements in the development of disease-specific treatments and novel therapeutic drug classes such as JAK inhibitors can potentially increase the Hand Eczema market growth. Moreover, the nascent drugs have opportunities as there are no pre-existing disease-specific approved therapies for Hand Eczema. Currently, only symptomatic relief can be provided and there is no therapy for a permanent cure. 

There is no pre-existing understanding of disease pathogenesis and universal diagnostic criteria for Hand Eczema. Readily availability of low-cost emollients and topical treatments may act as competitors for newer therapies. The considerable cost of drugs such as Dupilumab and Ruxolitinib is likely to limit patient access.

Scope of the Hand Eczema  Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom)]. 

• Key Hand Eczema  Companies: Basilea Pharmaceutica, Stiefel Laboratories, Regeneron, Sanofi, Leo Pharma, Japan Tobacco Inc., Incyte Corporation, Asana Biosciences, and others.

• Key Hand Eczema Therapies: Delgocitinib, Ruxolitinib, ASN002, and others

• Therapeutic Assessment: Hand Eczema marketed and emerging therapies

• Hand Eczema  Market Dynamics:  Hand Eczema market drivers and barriers.

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies.

• Unmet Needs, KOL’s views, Analyst’s views, Hand Eczema  Market Access and Reimbursement

Table of Contents

1. Hand Eczema Market Report Introduction

2. Hand Eczema Market Overview at a Glance

3. Hand Eczema Market Executive Summary

4. Disease Background and Overview

5. Hand Eczema Treatment and Management

6. Hand Eczema Epidemiology and Patient Population

7. Patient Journey 

8. Hand Eczema Market Key Insights

9. Hand Eczema Marketed Drugs

10. Hand Eczema Emerging Drugs

11. 7 Major Hand Eczema Market Analysis

12. Hand Eczema Market Outlook

13. Potential of Current and Emerging Therapies

14. KOL Views

15. Hand Eczema Market Drivers

16. Hand Eczema Market Barriers

17. Unmet Needs

18. SWOT Analysis

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Download the sample report @ Hand Eczema Market Assessment

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/